《大行報告》中金升雲頂新耀-B(01952.HK)目標價至85元 評級「跑贏行業」
中金髮表研究報告,指雲頂新耀-B(01952.HK)本週初宣佈與加拿大處於臨牀階段生物技術公司Providence就COVID-19疫苗訂立多份協議。其中,Providence已向公司授予授權知識產權的授權許可,用於在雲頂新耀COVID-19權益地區開發、製造、使用、推廣、銷售、要約銷售或進口COVID-19疫苗以供開發或商業化;及在雲頂新耀COVID-19權益地區外臨牀開發COVID-19疫苗的授權許可,僅用於支持COVID-19疫苗在雲頂新耀COVID-19權益地區內的臨牀試驗開發。Providence亦同意向公司轉讓開發、製造及商業化COVID-19疫苗所用的若幹生產製造及授權專有技術。
報告維持公司今明兩年每股虧損預測分別1.94元及1.69元人民幣,以現金流折現率爲估值基礎,考慮新冠候選疫苗未來銷售貢獻,上調目標價31.4%至85港元,維持「跑贏行業」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.